The GLP-1 Hangover
When prescriptions, coverage, or compounding access changes, appetite and weight can rebound fast. Here’s what the evidence—and policy shifts—say for 2026.
By TheMurrow Editorial
January 6, 2026
Key Points
- 1Expect rebound: STEP 1 found many regained about two‑thirds of prior semaglutide weight loss within a year after stopping.
- 2Know the stakes: SURMOUNT‑4 analysis reported 82% regained ≥25% of lost weight within one year after discontinuing tirzepatide.
- 3Plan for access churn: insurance changes, Medicaid pullbacks, and the compounding cliff can trigger abrupt stops—document outcomes and build a transition plan early.
A year ago, the story went like this: someone finally quieted the “food noise,” watched the scale drop—sometimes dramatically—and started buying clothes in sizes they hadn’t worn in a decade. Then the email arrived. A new prior authorization. An employer plan “update.” A pharmacy notice. A Medicaid bulletin. A compounded supply that suddenly disappeared.
The body didn’t wait for the paperwork to catch up. Appetite returned. Cravings sharpened. Weight crept back. The emotional whiplash felt oddly familiar to anyone who has ever quit caffeine or alcohol after months of relying on it.
People have started calling that crash the “GLP‑1 hangover.” The phrase is informal, but the experience is real—and the evidence is sobering.
“The ‘GLP‑1 hangover’ isn’t a lack of willpower. It’s what happens when chronic biology loses pharmacologic support.”
— — TheMurrow Editorial
What makes the moment uniquely fraught is timing. The U.S. is entering a period where access to semaglutide (Wegovy) and tirzepatide (Zepbound) is being reshaped not only by demand, but by policy: insurers tightening coverage, state Medicaid programs pulling back, and the FDA signaling an end to the era of “essentially copied” compounded versions as brand supply stabilizes.
The question for readers isn’t whether these drugs “work.” The better question is what happens when they stop—and what a realistic plan looks like when access is disrupted. Health & Wellness coverage
What people mean by the “GLP‑1 hangover”—and why it’s showing up now
The “GLP‑1 hangover” is less a medical diagnosis than a cultural shorthand for a specific cycle: meaningful weight loss on GLP‑1 or GLP‑1/GIP medications, followed by abrupt interruption and a rapid return of appetite and weight.
Several forces are converging in 2024–2026 to make that interruption more common. Many patients start these medications through employer coverage, then face coverage changes, including exclusions, tighter prior authorization rules, or step therapy. Others lose access through state Medicaid decisions that treat anti-obesity coverage as optional and therefore vulnerable when budgets tighten.
A third group—quietly enormous—relied on compounded copies during the shortage era. As brand supply stabilizes and regulators narrow “enforcement discretion,” those channels can close quickly, leaving patients scrambling.
The lived experience has a predictable arc. People describe a rush of relief while on medication: fewer intrusive thoughts about food, better portion control, less “white-knuckling.” When medication stops, that relief can vanish in days or weeks. The term “hangover” captures both the physical rebound and the emotional aftertaste—disappointment, shame, and the fear that they did something wrong.
Clinical trials do not describe shame. They do, however, describe what patients report: withdrawal from treatment leads to weight regain, and cardiometabolic gains tend to erode.
Several forces are converging in 2024–2026 to make that interruption more common. Many patients start these medications through employer coverage, then face coverage changes, including exclusions, tighter prior authorization rules, or step therapy. Others lose access through state Medicaid decisions that treat anti-obesity coverage as optional and therefore vulnerable when budgets tighten.
A third group—quietly enormous—relied on compounded copies during the shortage era. As brand supply stabilizes and regulators narrow “enforcement discretion,” those channels can close quickly, leaving patients scrambling.
The lived experience has a predictable arc. People describe a rush of relief while on medication: fewer intrusive thoughts about food, better portion control, less “white-knuckling.” When medication stops, that relief can vanish in days or weeks. The term “hangover” captures both the physical rebound and the emotional aftertaste—disappointment, shame, and the fear that they did something wrong.
Clinical trials do not describe shame. They do, however, describe what patients report: withdrawal from treatment leads to weight regain, and cardiometabolic gains tend to erode.
A real-world scenario playing out in clinics
A typical case looks like this:
- A patient loses substantial weight on Wegovy or Zepbound while combining medication with lifestyle changes.
- Coverage changes or compounded access ends.
- The patient stops abruptly, not by choice but by circumstance.
- Hunger, cravings, and weight regain accelerate—then the patient blames themselves.
A more honest interpretation is that obesity behaves like other chronic conditions: treatment often requires maintenance, not a short course and a victory lap.
- A patient loses substantial weight on Wegovy or Zepbound while combining medication with lifestyle changes.
- Coverage changes or compounded access ends.
- The patient stops abruptly, not by choice but by circumstance.
- Hunger, cravings, and weight regain accelerate—then the patient blames themselves.
A more honest interpretation is that obesity behaves like other chronic conditions: treatment often requires maintenance, not a short course and a victory lap.
A typical “GLP‑1 hangover” arc
- ✓Meaningful weight loss on Wegovy/Zepbound while supported by coverage or reliable supply
- ✓Abrupt interruption due to prior auth, plan exclusion, Medicaid changes, or compounding loss
- ✓Rapid return of hunger, cravings, and “food noise” within days or weeks
- ✓Weight regain that can feel like personal failure—but often reflects rebound biology
What the best evidence says after stopping semaglutide: the STEP 1 extension
The cleanest data on post‑GLP‑1 regain comes from a study designed to answer the uncomfortable question: what happens when people stop?
In the STEP 1 trial extension of semaglutide 2.4 mg (Wegovy), participants received medication plus lifestyle intervention, then discontinued the drug and were followed. By week 120—about a year after stopping—people previously on semaglutide regained 11.6 percentage points of weight loss after withdrawal. Researchers summarized that as regaining about two‑thirds of prior weight loss. (STEP 1 extension, published on PubMed: https://pubmed.ncbi.nlm.nih.gov/35441470/)
Those numbers matter because they puncture a popular fantasy: that the medication “resets” the body permanently. For many, it doesn’t. The physiology that drove weight gain often remains—and when the pharmacologic pressure comes off, the body tends to drift back toward its earlier set point.
The trial also tracked metabolic markers. After stopping semaglutide, cardiometabolic improvements reverted toward baseline. That doesn’t mean treatment was pointless; it means treatment was doing ongoing work.
In the STEP 1 trial extension of semaglutide 2.4 mg (Wegovy), participants received medication plus lifestyle intervention, then discontinued the drug and were followed. By week 120—about a year after stopping—people previously on semaglutide regained 11.6 percentage points of weight loss after withdrawal. Researchers summarized that as regaining about two‑thirds of prior weight loss. (STEP 1 extension, published on PubMed: https://pubmed.ncbi.nlm.nih.gov/35441470/)
Those numbers matter because they puncture a popular fantasy: that the medication “resets” the body permanently. For many, it doesn’t. The physiology that drove weight gain often remains—and when the pharmacologic pressure comes off, the body tends to drift back toward its earlier set point.
The trial also tracked metabolic markers. After stopping semaglutide, cardiometabolic improvements reverted toward baseline. That doesn’t mean treatment was pointless; it means treatment was doing ongoing work.
“Stopping a GLP‑1 can look like ‘relapse,’ but the more accurate word is ‘rebound.’”
— — TheMurrow Editorial
11.6 percentage points
In the STEP 1 trial extension, participants regained 11.6 percentage points of lost weight by week 120—about one year after stopping semaglutide.
≈ two‑thirds
Researchers summarized STEP 1 extension regain as recouping about two‑thirds of prior weight loss after semaglutide withdrawal.
What readers should take from STEP 1
Three practical implications stand out:
- Regain is common. The trial structure makes clear it’s not a personal anomaly.
- Maintenance matters. If obesity is chronic, the framework resembles hypertension care more than a short antibiotic course.
- A ‘plan B’ should be discussed early. Waiting until coverage collapses leaves patients reacting in panic rather than adjusting strategically.
The data isn’t a verdict against GLP‑1s. It’s a warning against treating them like temporary scaffolding.
- Regain is common. The trial structure makes clear it’s not a personal anomaly.
- Maintenance matters. If obesity is chronic, the framework resembles hypertension care more than a short antibiotic course.
- A ‘plan B’ should be discussed early. Waiting until coverage collapses leaves patients reacting in panic rather than adjusting strategically.
The data isn’t a verdict against GLP‑1s. It’s a warning against treating them like temporary scaffolding.
Key takeaway
STEP 1 doesn’t argue against GLP‑1s; it argues against surprise discontinuation. For many, the medication is providing ongoing physiologic pressure, not a permanent reset.
Tirzepatide withdrawal data: SURMOUNT‑4 and the price of discontinuation
Tirzepatide (Zepbound/Mounjaro) intensified the conversation because results during treatment were so compelling that many assumed the rebound would be gentler. Evidence suggests otherwise.
The SURMOUNT‑4 trial used a design that mimics real life. Participants took tirzepatide for 36 weeks (a lead‑in period), then were randomized either to continue tirzepatide or switch to placebo for 52 weeks.
A post‑hoc analysis published online Nov 24, 2025 in JAMA Internal Medicine reported a striking statistic: among participants who discontinued (the placebo arm), 82% regained ≥25% of their initial weight reduction within 1 year of withdrawal. The analysis also found that greater weight regain correlated with greater reversal of cardiometabolic improvements. (JAMA Internal Medicine link: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273)
A more accessible summary echoed the core finding: those who continued treatment lost more weight; those who stopped regained and saw risk-factor gains reverse. (Cornell news summary: https://news.cornell.edu/stories/2023/12/discontinuing-anti-obesity-drug-tirzepatide-leads-weight-regain)
The numbers are not just statistics. They are a preview of what thousands of patients may face as coverage tightens.
The SURMOUNT‑4 trial used a design that mimics real life. Participants took tirzepatide for 36 weeks (a lead‑in period), then were randomized either to continue tirzepatide or switch to placebo for 52 weeks.
A post‑hoc analysis published online Nov 24, 2025 in JAMA Internal Medicine reported a striking statistic: among participants who discontinued (the placebo arm), 82% regained ≥25% of their initial weight reduction within 1 year of withdrawal. The analysis also found that greater weight regain correlated with greater reversal of cardiometabolic improvements. (JAMA Internal Medicine link: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273)
A more accessible summary echoed the core finding: those who continued treatment lost more weight; those who stopped regained and saw risk-factor gains reverse. (Cornell news summary: https://news.cornell.edu/stories/2023/12/discontinuing-anti-obesity-drug-tirzepatide-leads-weight-regain)
The numbers are not just statistics. They are a preview of what thousands of patients may face as coverage tightens.
82%
In a SURMOUNT‑4 post‑hoc analysis, 82% of participants who discontinued tirzepatide regained ≥25% of initial weight reduction within 1 year.
Multiple perspectives: “lifelong medication” vs. “sustainable independence”
There is a real debate here, and it deserves respect.
One perspective argues that framing GLP‑1s as long-term therapy is rational: obesity is chronic, and many chronic diseases require ongoing pharmacologic treatment. From that view, the ethical failure isn’t dependence—it’s denying maintenance care.
Another perspective worries about the societal implications: cost, supply constraints, and the psychological toll of believing health is only available through a prescription. People also raise concerns about what happens when long-term access is unstable.
The SURMOUNT‑4 and STEP 1 data don’t settle the debate. They clarify the stakes. Discontinuation commonly leads to regain, and pretending otherwise sets patients up for disappointment.
One perspective argues that framing GLP‑1s as long-term therapy is rational: obesity is chronic, and many chronic diseases require ongoing pharmacologic treatment. From that view, the ethical failure isn’t dependence—it’s denying maintenance care.
Another perspective worries about the societal implications: cost, supply constraints, and the psychological toll of believing health is only available through a prescription. People also raise concerns about what happens when long-term access is unstable.
The SURMOUNT‑4 and STEP 1 data don’t settle the debate. They clarify the stakes. Discontinuation commonly leads to regain, and pretending otherwise sets patients up for disappointment.
Key Insight
The withdrawal data doesn’t decide whether GLP‑1s “should” be lifelong. It shows what commonly happens when they’re interrupted without a continuity plan.
Why access is getting shakier: insurance churn, Medicaid pullbacks, and the compounding cliff
The “GLP‑1 hangover” is not only biology. It’s also bureaucracy.
Coverage changes often arrive suddenly: a new employer plan year, a benefits redesign, a payer’s revised prior authorization criteria. Patients who were stable for months can discover they are newly “non-covered,” or required to restart step therapy.
Medicaid adds another layer of volatility because anti-obesity drug coverage is often treated as optional. When state budgets tighten, those optional benefits become political targets.
A concrete example came from North Carolina Medicaid, which announced coverage changes due to funding shortfalls. Effective Oct 1, 2025, NC Medicaid discontinued coverage of GLP‑1s for treatment of obesity. The bulletin specified that GLP‑1s remain covered for certain other indications (such as diabetes and specific cardiovascular-risk reduction), and that Wegovy, Zepbound, and Saxenda were removed from the Preferred Drug List for weight management; Saxenda would no longer be covered for any indication, according to the bulletin. (NC Medicaid bulletin: https://medicaid.ncdhhs.gov/blog/2025/09/05/nc-medicaid-change-coverage-glp-1-weight-management-medications)
This is not merely a North Carolina story. It’s a template: budget pressure, optional benefits, abrupt interruption. Business & Money reporting
Coverage changes often arrive suddenly: a new employer plan year, a benefits redesign, a payer’s revised prior authorization criteria. Patients who were stable for months can discover they are newly “non-covered,” or required to restart step therapy.
Medicaid adds another layer of volatility because anti-obesity drug coverage is often treated as optional. When state budgets tighten, those optional benefits become political targets.
A concrete example came from North Carolina Medicaid, which announced coverage changes due to funding shortfalls. Effective Oct 1, 2025, NC Medicaid discontinued coverage of GLP‑1s for treatment of obesity. The bulletin specified that GLP‑1s remain covered for certain other indications (such as diabetes and specific cardiovascular-risk reduction), and that Wegovy, Zepbound, and Saxenda were removed from the Preferred Drug List for weight management; Saxenda would no longer be covered for any indication, according to the bulletin. (NC Medicaid bulletin: https://medicaid.ncdhhs.gov/blog/2025/09/05/nc-medicaid-change-coverage-glp-1-weight-management-medications)
This is not merely a North Carolina story. It’s a template: budget pressure, optional benefits, abrupt interruption. Business & Money reporting
“Access isn’t a personal health behavior. It’s a policy variable—and patients are living inside the math.”
— — TheMurrow Editorial
The compounding cliff: when the workaround stops working
During shortages, many patients turned to compounded versions—sometimes through legitimate compounding pharmacies, sometimes through far murkier channels. The FDA has repeatedly emphasized that compounded drugs are not FDA‑approved and can carry quality and safety risks, particularly when they are “essentially copies” of commercially available products.
The access crunch is tightening because the shortage era is changing. The FDA stated that the semaglutide injection shortage was resolved on Feb 21, 2025. The agency also described a temporary enforcement discretion period—stating it did not intend to take action against certain compounding practices until April 22, 2025 (503A) and until May 22, 2025 (503B), with details later narrowed/confirmed in updates referenced by the agency. (FDA update: https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)
For patients, the practical implication is stark: the workaround that made treatment affordable or available may vanish—or become riskier if pursued through unreliable sources.
The access crunch is tightening because the shortage era is changing. The FDA stated that the semaglutide injection shortage was resolved on Feb 21, 2025. The agency also described a temporary enforcement discretion period—stating it did not intend to take action against certain compounding practices until April 22, 2025 (503A) and until May 22, 2025 (503B), with details later narrowed/confirmed in updates referenced by the agency. (FDA update: https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)
For patients, the practical implication is stark: the workaround that made treatment affordable or available may vanish—or become riskier if pursued through unreliable sources.
Feb 21, 2025
The FDA stated the semaglutide injection shortage was resolved on Feb 21, 2025—reshaping when “essentially copied” compounding may be targeted.
Editor’s Note
The FDA emphasizes compounded GLP‑1 drugs are not FDA‑approved. Enforcement discretion was tied to shortage status and dates like April 22, 2025 (503A) and May 22, 2025 (503B).
The emotional “hangover”: shame, “food noise,” and the trap of self-blame
The clinical literature measures weight and lab values. Patients live inside appetite, identity, and stigma.
Many people on GLP‑1s report a mental shift: fewer obsessive food thoughts, easier restraint, less internal negotiation. When medication stops, the return of appetite can feel like betrayal—by the body, by the healthcare system, and sometimes by the patient’s own hope.
The most corrosive part of the “hangover” may be the story people tell themselves: I failed. Trial evidence points elsewhere. When participants in STEP 1 regained about two-thirds of prior weight loss after stopping, they weren’t confessing moral weakness. They were experiencing the expected result of removing an active therapy.
The shame spiral can also be intensified by social narratives that treat weight loss as a one-way transformation. When regain begins, some people withdraw from care or avoid follow-up appointments precisely when they most need support.
Many people on GLP‑1s report a mental shift: fewer obsessive food thoughts, easier restraint, less internal negotiation. When medication stops, the return of appetite can feel like betrayal—by the body, by the healthcare system, and sometimes by the patient’s own hope.
The most corrosive part of the “hangover” may be the story people tell themselves: I failed. Trial evidence points elsewhere. When participants in STEP 1 regained about two-thirds of prior weight loss after stopping, they weren’t confessing moral weakness. They were experiencing the expected result of removing an active therapy.
The shame spiral can also be intensified by social narratives that treat weight loss as a one-way transformation. When regain begins, some people withdraw from care or avoid follow-up appointments precisely when they most need support.
A case study that’s becoming common
Consider two patients who both lose significant weight on medication.
- Patient A has stable employer coverage and can continue treatment. Weight loss continues or stabilizes.
- Patient B changes jobs, loses coverage, and cannot afford the medication out-of-pocket. Within months, appetite returns and weight begins to climb.
Both patients may have started with equal effort. Their outcomes diverge because of access, not character. The “GLP‑1 hangover” is often a structural problem wearing a personal mask.
- Patient A has stable employer coverage and can continue treatment. Weight loss continues or stabilizes.
- Patient B changes jobs, loses coverage, and cannot afford the medication out-of-pocket. Within months, appetite returns and weight begins to climb.
Both patients may have started with equal effort. Their outcomes diverge because of access, not character. The “GLP‑1 hangover” is often a structural problem wearing a personal mask.
How outcomes diverge when access diverges
Before
- Patient A—stable employer coverage
- continues treatment
- weight loss continues or stabilizes
After
- Patient B—job change
- coverage loss
- stops therapy
- appetite returns and weight begins to climb
What clinicians and policy makers often miss
Even when discontinuation is medically safe, it’s psychologically disruptive. The return of hunger isn’t just uncomfortable; it can feel like losing a new sense of normal. That’s why access planning should be treated as part of care, not an administrative afterthought.
Plan B without false promises: what patients can do when GLP‑1 access changes
Readers deserve realism, not platitudes. The evidence in STEP 1 and SURMOUNT‑4 suggests that stopping commonly leads to regain. That doesn’t mean people are helpless. It does mean that a “plan B” should focus on mitigating rebound, not pretending it won’t happen.
Practical steps to consider (discuss with a clinician)
- Don’t stop in silence. If coverage is ending, tell the prescribing clinician early. Time matters when forming a transition plan.
- Document outcomes. Weight change and cardiometabolic markers that improved on therapy can support medical-necessity arguments in coverage disputes.
- Ask about continuity options. Some patients may qualify under other covered indications depending on their medical history; others may not. The NC Medicaid bulletin, for example, distinguishes obesity treatment from other indications.
- Plan for appetite return. Expect hunger and cravings to increase after discontinuation; normalize the experience rather than treating it as a personal failure.
- Be cautious about compounded sources. The FDA has stated compounded versions are not FDA-approved and has tied enforcement discretion to shortage status and specific dates. Patients should understand the legal and safety terrain before pursuing compounded copies.
- Document outcomes. Weight change and cardiometabolic markers that improved on therapy can support medical-necessity arguments in coverage disputes.
- Ask about continuity options. Some patients may qualify under other covered indications depending on their medical history; others may not. The NC Medicaid bulletin, for example, distinguishes obesity treatment from other indications.
- Plan for appetite return. Expect hunger and cravings to increase after discontinuation; normalize the experience rather than treating it as a personal failure.
- Be cautious about compounded sources. The FDA has stated compounded versions are not FDA-approved and has tied enforcement discretion to shortage status and specific dates. Patients should understand the legal and safety terrain before pursuing compounded copies.
Plan-B checklist (bring to your next appointment)
- ✓Tell your prescriber early if coverage is ending—time matters
- ✓Document weight change and cardiometabolic markers to support medical-necessity appeals
- ✓Ask whether other covered indications might apply in your medical history
- ✓Expect hunger/cravings to return; treat it as rebound biology, not moral failure
- ✓Understand FDA stance and risks before pursuing compounded copies
A note on compounded medications: access vs. risk
Some patients used compounded versions responsibly through reputable pharmacies during shortages; others were exposed to inconsistent products. The FDA’s position is explicit: compounded drugs are not FDA‑approved, and enforcement increasingly targets “essentially copies” once shortages are resolved. As semaglutide supply stabilized with a shortage resolution dated Feb 21, 2025, the policy environment shifted. (FDA update link above.)
Patients can reasonably feel trapped between affordability and safety. The right response from institutions is not moralizing; it’s building transparent, durable access pathways.
Patients can reasonably feel trapped between affordability and safety. The right response from institutions is not moralizing; it’s building transparent, durable access pathways.
What a smarter public conversation would sound like
The GLP‑1 moment has produced two bad narratives. One treats these medications as vanity shortcuts. The other treats them as a permanent magic spell.
The evidence supports neither. Trials show substantial weight loss during treatment—and substantial regain after discontinuation. That combination points to a more nuanced truth: for many people, GLP‑1s are closer to ongoing management than a finite cure.
A smarter public conversation would also acknowledge policy realities. If society expects long-term treatment, then coverage must be stable. When coverage is unstable, patients will cycle on and off therapy, producing the very rebound that critics then use as evidence of failure.
Medicaid policy illustrates the point. North Carolina’s Oct 1, 2025 change made GLP‑1 obesity coverage contingent on budgets. Private insurance often behaves similarly but with less public notice. Meanwhile, the end of widespread compounding access after Feb–May 2025 policy shifts tightens the vise.
None of this is a reason to abandon GLP‑1s. It’s a reason to stop treating access as a private matter and start treating it as health infrastructure. more GLP‑1 explainers
The evidence supports neither. Trials show substantial weight loss during treatment—and substantial regain after discontinuation. That combination points to a more nuanced truth: for many people, GLP‑1s are closer to ongoing management than a finite cure.
A smarter public conversation would also acknowledge policy realities. If society expects long-term treatment, then coverage must be stable. When coverage is unstable, patients will cycle on and off therapy, producing the very rebound that critics then use as evidence of failure.
Medicaid policy illustrates the point. North Carolina’s Oct 1, 2025 change made GLP‑1 obesity coverage contingent on budgets. Private insurance often behaves similarly but with less public notice. Meanwhile, the end of widespread compounding access after Feb–May 2025 policy shifts tightens the vise.
None of this is a reason to abandon GLP‑1s. It’s a reason to stop treating access as a private matter and start treating it as health infrastructure. more GLP‑1 explainers
The deeper implication for readers
If you’re on one of these drugs—or considering one—ask a question that rarely appears in glossy before-and-after stories: What happens if I have to stop? The answer isn’t meant to scare you. It’s meant to protect you from surprise.
The “GLP‑1 hangover” is not inevitable for every patient, but it is predictable enough that the ethical move is to plan for it.
The “GLP‑1 hangover” is not inevitable for every patient, but it is predictable enough that the ethical move is to plan for it.
Conclusion: The hangover isn’t the story. The system is.
The rebound after stopping GLP‑1s is not a scandal. It’s a data-backed feature of treating a chronic condition with a medication that actively changes appetite and physiology.
The scandal—if there is one—is how casually the system sets people up for abrupt discontinuation. STEP 1 showed that by about a year after stopping semaglutide, participants regained 11.6 percentage points of weight loss, roughly two-thirds of what they had lost, with cardiometabolic improvements sliding toward baseline. SURMOUNT‑4’s post‑hoc analysis found that 82% of those who discontinued tirzepatide regained at least 25% of their initial weight reduction within a year, and that greater regain tracked with greater reversal of metabolic gains.
At the policy level, the ground is shifting: the FDA declared the semaglutide injection shortage resolved on Feb 21, 2025, and enforcement discretion for certain compounding practices was tied to dates like April 22, 2025 (503A) and May 22, 2025 (503B). State programs can pull coverage quickly, as North Carolina Medicaid did effective Oct 1, 2025 for obesity treatment.
Readers don’t need another morality tale about weight. They need a clear-eyed understanding of what the evidence shows and what the policy environment can do to a body mid-journey. The best protection against the “GLP‑1 hangover” is not grit. It’s planning, documentation, and a healthcare system that treats continuity of care as more than a benefit design detail. subscribe to our newsletter
The scandal—if there is one—is how casually the system sets people up for abrupt discontinuation. STEP 1 showed that by about a year after stopping semaglutide, participants regained 11.6 percentage points of weight loss, roughly two-thirds of what they had lost, with cardiometabolic improvements sliding toward baseline. SURMOUNT‑4’s post‑hoc analysis found that 82% of those who discontinued tirzepatide regained at least 25% of their initial weight reduction within a year, and that greater regain tracked with greater reversal of metabolic gains.
At the policy level, the ground is shifting: the FDA declared the semaglutide injection shortage resolved on Feb 21, 2025, and enforcement discretion for certain compounding practices was tied to dates like April 22, 2025 (503A) and May 22, 2025 (503B). State programs can pull coverage quickly, as North Carolina Medicaid did effective Oct 1, 2025 for obesity treatment.
Readers don’t need another morality tale about weight. They need a clear-eyed understanding of what the evidence shows and what the policy environment can do to a body mid-journey. The best protection against the “GLP‑1 hangover” is not grit. It’s planning, documentation, and a healthcare system that treats continuity of care as more than a benefit design detail. subscribe to our newsletter
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering health & wellness.
Frequently Asked Questions
What is a “GLP‑1 hangover”?
“GLP‑1 hangover” is an informal term people use for the rebound they feel after stopping GLP‑1 or GLP‑1/GIP weight-loss medications: appetite returns, cravings intensify, “food noise” increases, and weight regain can follow. Clinical trial withdrawal evidence supports that regain after discontinuation is common, which helps explain why the experience feels so predictable across patients.
How much weight do people regain after stopping semaglutide (Wegovy)?
In the STEP 1 trial extension, participants who stopped semaglutide 2.4 mg regained 11.6 percentage points of weight loss by week 120 (about a year after stopping). Researchers described this as regaining about two‑thirds of prior weight loss, and cardiometabolic improvements moved back toward baseline after withdrawal.
What does the evidence show for tirzepatide (Zepbound) after discontinuation?
In SURMOUNT‑4, participants took tirzepatide for 36 weeks, then some were switched to placebo for 52 weeks. A post‑hoc analysis published online Nov 24, 2025 in JAMA Internal Medicine reported that 82% of those who discontinued regained ≥25% of their initial weight reduction within a year, with greater regain linked to greater reversal of metabolic improvements.
Why are people losing access to GLP‑1 medications in 2025–2026?
Access disruptions often stem from insurance coverage changes (exclusions, tighter prior authorization, step therapy), Medicaid pullbacks when states face budget pressure, and the tightening of the compounding pathway as the FDA determines shortages have resolved. These are structural issues that can affect patients regardless of adherence or clinical benefit.
